BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23443316)

  • 21. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
    Razmara M; Monazzam A; Skogseid B
    Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy.
    Huang H; Kang R; Wang J; Luo G; Yang W; Zhao Z
    Autophagy; 2013 Feb; 9(2):175-95. PubMed ID: 23169238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
    Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
    PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W; Ye Q; Liu S; She QB
    Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transforming Growth Factor-β Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion.
    Gupta S; Hau AM; Al-Ahmadie HA; Harwalkar J; Shoskes AC; Elson P; Beach JR; Hussey GS; Schiemann WP; Egelhoff TT; Howe PH; Hansel DE
    Am J Pathol; 2016 May; 186(5):1351-60. PubMed ID: 26988652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways].
    Fu Y; Zhang Y; Zhang F; Liu J; Gui R
    Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):780-4. PubMed ID: 26462781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.
    Lee SL; Chou CC; Chuang HC; Hsu EC; Chiu PC; Kulp SK; Byrd JC; Chen CS
    PLoS One; 2013; 8(6):e67149. PubMed ID: 23840605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
    Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
    Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
    Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
    J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
    Gen Y; Yasui K; Nishikawa T; Yoshikawa T
    Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition.
    Matsubara S; Tsukasa K; Kuwahata T; Takao S
    Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.
    Vo BT; Morton D; Komaragiri S; Millena AC; Leath C; Khan SA
    Endocrinology; 2013 May; 154(5):1768-79. PubMed ID: 23515290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
    Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
    Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer.
    Javle M; Li Y; Tan D; Dong X; Chang P; Kar S; Li D
    PLoS One; 2014; 9(1):e85942. PubMed ID: 24465802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TSC1 activates TGF-β-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition.
    Thien A; Prentzell MT; Holzwarth B; Kläsener K; Kuper I; Boehlke C; Sonntag AG; Ruf S; Maerz L; Nitschke R; Grellscheid SN; Reth M; Walz G; Baumeister R; Neumann-Haefelin E; Thedieck K
    Dev Cell; 2015 Mar; 32(5):617-30. PubMed ID: 25727005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
    Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
    Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.